Seeking Alpha

Avanir Pharmaceuticals (AVNR) reports mixed FQ4 results, matching loss estimates on a per share...

Avanir Pharmaceuticals (AVNR) reports mixed FQ4 results, matching loss estimates on a per share basis but missing on revenue. Shares are trading higher after hours however, as investors appear to be focused on the company's 561% Y/Y jump in profit due to royalty payments from Abreva and Nuedexta. Shares +2.6% AH.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|